Exact Mass: 415.2107

Exact Mass Matches: 415.2107

Found 500 metabolites which its exact mass value is equals to given mass value 415.2107, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Alpinine

2,3,8,10,11-Pentamethoxy-16-methylrheadan #

C23H29NO6 (415.1995)

Naltriben

C26H25NO4 (415.1783)

D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists

Mavelertinib

C18H22FN9O2 (415.188)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

Rupatadine

13-chloro-2-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3(8),4,6,11,13-hexaene

C26H26ClN3 (415.1815)

R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Rupatadine is a second-generation tricyclic H1-antihistamine.

4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol,7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-

22-(cyclopropylmethyl)-11,14-dioxa-22-azaheptacyclo[13.9.1.0^{1,13}.0^{2,21}.0^{4,12}.0^{5,10}.0^{19,25}]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol

C26H25NO4 (415.1783)

CID 9844747

4-fluoro-N-(2-{4-[2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl}ethyl)benzamide

C22H26FN3O4 (415.1907)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Flesinoxan is a hypotensive agent and a potent, high affinity and selective 5-hydroxytryptamine1A (5-HT1A) receptor agonist with an EC50 value of 24 nM. Flesinoxan also has effective anxiolytic/antidepressant effects[1][2][3].

(2S)-2-[[(2S)-2-Amino-3-(1H-imidazol-5-yl)propanoyl]-(2-benzamidoethyl)amino]-4-methylpentanoic acid

2-[2-Amino-N-(2-{[hydroxy(phenyl)methylidene]amino}ethyl)-3-(1H-imidazol-5-yl)propanamido]-4-methylpentanoate

C21H29N5O4 (415.2219)

Protostemotinine

(1S,4S,13S)-4-methoxy-3,11-dimethyl-4-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]spiro[5-azatricyclo[8.3.0.01,5]tridec-10-ene-13,5-furan]-2,12-dione

C23H29NO6 (415.1995)

Protostemotinine is a natural product found in Stemona sessilifolia, Stemona kerrii, and Stemona japonica with data available. Protostemotinine is an alkaloid isolated from the roots and rhizomes of Stemona sessilifolia. Protostemotinine is an alkaloid isolated from the roots and rhizomes of Stemona sessilifolia.

MMV020512

C25H25N3O3 (415.1896)

2-{[(2S)-1-[(2S)-2-(2-aminoacetamido)-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}acetic acid

C20H25N5O5 (415.1856)

Phe Leu His

C21H29N5O4 (415.2219)

C20H25N5O5 (415.1856)

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]propanamido]-3-methylbutanamido]-3-carbamoylpropanoic acid

C18H33N5O6 (415.2431)

Tyr His Pro

C20H25N5O5 (415.1856)

Asn Trp Pro

C20H25N5O5 (415.1856)

(3S)-3-{[(1S)-5-amino-1-[(carboxymethyl)carbamoyl]pentyl]carbamoyl}-3-[(2S)-pyrrolidin-2-ylformamido]propanoic acid

C17H29N5O7 (415.2067)

Phe His Leu

C21H29N5O4 (415.2219)

Pro Gly Asp Lys

(2S)-6-amino-2-[(2S)-3-carboxy-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanamido]hexanoic acid

C17H29N5O7 (415.2067)

Pro Gly Gly Trp

(2S)-3-(1H-indol-3-yl)-2-(2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}acetamido)propanoic acid

C20H25N5O5 (415.1856)

Pro Gly Lys Asp

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}hexanamido]butanedioic acid

C17H29N5O7 (415.2067)

Pro Gly Arg Ser

(2S)-2-[(2S)-5-carbamimidamido-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}pentanamido]-3-hydroxypropanoic acid

C16H29N7O6 (415.2179)

Pro Gly Ser Arg

(2S)-5-carbamimidamido-2-[(2S)-3-hydroxy-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanamido]pentanoic acid

C16H29N7O6 (415.2179)

Pro Gly Trp Gly

2-[(2S)-3-(1H-indol-3-yl)-2-{2-[(2S)-pyrrolidin-2-ylformamido]acetamido}propanamido]acetic acid

C20H25N5O5 (415.1856)

2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}acetic acid

C16H29N7O6 (415.2179)

Asn Pro Trp

C20H25N5O5 (415.1856)

Ser Val Asn Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylbutanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C17H29N5O7 (415.2067)

Ser Val Pro Asn

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylbutanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C17H29N5O7 (415.2067)

Thr Ala Pro Gln

(2S)-2-{[(2S)-1-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]propanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanoic acid

C17H29N5O7 (415.2067)

Thr Ala Gln Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]propanamido]-4-carbamoylbutanoyl]pyrrolidine-2-carboxylic acid

C17H29N5O7 (415.2067)

Trp Asn Pro

C20H25N5O5 (415.1856)

C23H30ClN3O2 (415.2026)

Donepezil Hydrochloride

C24H30ClNO3 (415.1914)

ML228 (CID-46742353) is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF[1][2].

1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine Maleate

C23H29NO4S (415.1817)

L-Phenylalanyl-L-histidyl-L-leucine

C21H29N5O4 (415.2219)

4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]piperidine

C23H24F3N3O (415.1871)

1-(phenylmethyl)-N-(2,4,6-trimethylphenyl)sulfonyl-4-piperidinecarbohydrazide

C22H29N3O3S (415.193)

H-Pro-his-tyr-OH

C20H25N5O5 (415.1856)

L-Leucyl-L-phenylalanyl-L-histidine

C21H29N5O4 (415.2219)

[1-acetyl-4-tert-butyl-3,6-bis(tert-butylsulfanyl)-3,6-dihydro-2H-pyridin-2-yl] acetate

C21H37NO3S2 (415.2215)

(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL

C21H23F2N5O2 (415.182)

(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL

C21H23F2N5O2 (415.182)

1-{[(1E)-(3-Hydroxy-2-methyl-5-{[(trihydroxy-lambda^5^-phosphanyl)oxy]methyl}pyridin-4-YL)methylidene]amino}undecan-2-one

C19H32N2O6P+ (415.1998)

Rupatadine

C26H26ClN3 (415.1815)

R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist

N-[4-(4-methylphenoxy)phenyl]-2-[2-(2-oxopyrrolidin-1-yl)anilino]acetamide

C25H25N3O3 (415.1896)

N-[[4-(2-propan-2-yl-5-pyridin-4-ylpyrimidin-4-yl)cyclohexyl]methyl]pyridine-3-carboxamide

C25H29N5O (415.2372)

4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol,7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-

22-(cyclopropylmethyl)-11,14-dioxa-22-azaheptacyclo[13.9.1.0^{1,13}.0^{2,21}.0^{4,12}.0^{5,10}.0^{19,25}]pentacosa-4(12),5,7,9,15,17,19(25)-heptaene-2,16-diol

C26H25NO4 (415.1783)

17-O-deacetylvindolinium

C23H31N2O5+ (415.2233)

A vinca alkaloid cation that is the conjugate acid of 17-O-deacetylvindoline.

(10S,12S)-3-acetyl-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.02,10.04,9.015,20]henicosa-4,6,8,15,17,19-hexaene-13,21-dione

C25H25N3O3 (415.1896)

(2S)-2-[[(2S)-2-Amino-3-(1H-imidazol-5-yl)propanoyl]-(2-benzamidoethyl)amino]-4-methylpentanoic acid

C21H29N5O4 (415.2219)

smenospongines C

ALM301

C25H25N3O3 (415.1896)

ALM301 is an orally active highly specific AKT inhibitor with IC50 values of 0.13 μM, 0.09 μM and 2.75 μM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth[1].

GSK163090

C25H29N5O (415.2372)

GSK163090 is a potent, selective and orally active 5-HT1A/1B/1D receptor antagonist with pKi values of 9.4/8.5/9.7, respectively. GSK163090 inhibits the functional activity of serotonin reuptake transporter (SerT) with a pKi value of 6.1. GSK163090 has antidepressant and anxiolytic activities[1].

Ninerafaxstat

C22H29N3O5 (415.2107)

Ninerafaxstat (IMB-1018972) is a novel mitotropic agent. Ninerafaxstat increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat can be used for the research of cardiovascular diseases[1].

SR59230A

C23H29NO6 (415.1995)

SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist[1] with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively[2].

4,5,24,24-tetramethyl-25,26-dioxa-7-azaheptacyclo[21.2.1.0¹,²⁰.0⁴,¹⁹.0⁵,¹⁶.0⁶,¹⁴.0⁸,¹³]hexacosa-6(14),8,10,12,18,20-hexaen-22-one

C27H29NO3 (415.2147)

4-methoxy-3-methyl-5-[(1s,2r,3s,4e,11s)-3-methyl-11-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.0²,⁶]tridec-6-en-4-ylidene]furan-2-one

C23H29NO6 (415.1995)

6-hydroxy-11-methyl-5-methylidene-12-oxo-16-oxa-13-azahexacyclo[9.6.3.2⁴,⁷.0¹,¹⁰.0²,⁷.0¹³,¹⁷]docosan-8-yl acetate

C24H33NO5 (415.2359)

10,13-dihydroxy-1,5,6-trimethyl-8-(2-methylpropyl)-19-oxa-9-azapentacyclo[14.2.1.0²,¹⁴.0³,¹¹.0⁷,¹¹]nonadeca-4,9-diene-12,15-dione

C24H33NO5 (415.2359)

(1'r,2s,11's)-3-methoxy-4,4'-dimethyl-11'-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-10'-azaspiro[furan-2,2'-tricyclo[8.3.0.0¹,⁵]tridecan]-4'-ene-3',5-dione

C23H29NO6 (415.1995)

(2r,3s,3as,5's,5as,7r,9ar,9bs)-2'-hydroxy-3-[(1e,3r)-3-hydroxybut-1-en-1-yl]-5'-[(1r)-1-hydroxyethyl]-7,9b-dimethyl-3,3a,5a,6,7,8,9,9a-octahydro-5'h-spiro[cyclopenta[a]naphthalene-2,3'-pyrrole]-1,4'-dione

(2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-{[1-(hydroxymethyl)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-5-yl]oxy}oxane-3,4,5-triol

C19H29NO9 (415.1842)